ClinicalTrials.gg
WithdrawnNCT04841512Updated Mar 17, 2022

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

A Phase 1/2 interventional study of XT-150 in Osteoarthritis, Spine, sponsored by Xalud Therapeutics, Inc.. Withdrawn at 1 site in Australia. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by Xalud Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
COVID - Lack of recruitment
Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.

Read the detailed description

This is a Phase 1, safety and efficacy study of XT-150 in adult participants experiencing back pain due to inflammation of the facet joint osteoarthritis (FJOA) and who are eligible for intra-synovial glucocorticoid injection, or radiofrequency ablation of medial branches of the primary dorsal ramus of the exiting nerve root, which innervates the adjacent facet joints.

02

Conditions studied

  • Osteoarthritis, Spine

Browse trials for

Keywords

  • gene therapy
  • non-viral plasmid
  • osteoarthritis
03

In context

Osteoarthritis

2,974 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Lead sponsor

Xalud Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, between 18 and 90 years of age, inclusive.
  2. Sufficiently severe facet arthropathy (OA) of lumbar facets as determined by imaging, eg. CT or MRI, to establish an underlying basis of disease, as determined by usual bony and ligamentous signs of OA.
  3. Complaint of nociceptive, mechanical pain of lumbar spine, in particular pain localized to paramedian axis as opposed to midline or radicular. Radicular pain as a secondary finding may be allowed if it is addition to mechanical pain and can be clinically distinguished by subject
  4. Low Back Pain (LBP) worsened by activity or motion of region
  5. Have had a positive diagnostic facet pain block with lignocaine; admittance if subject gains 50% relief of pain within 30 minutes of test injection
  6. Be free of local or intra-articular infection, tumor or other causes of localized LBP, for example Including spondylolysis/pars defect, and adjacent vertebral body compression fracture based on MRI evaluation.
  7. Symptomatic disease because of osteoarthritis, established by imaging of facet joint and defined as a worst pain of at least 40 at any time during the preceding week (based on scale of 0 to 100, with 100 representing "pain as bad as you can imagine") using Visual Analog Scale (VAS).
  8. Stable analgesic regimen during the 4 weeks prior to enrollment.
  9. Inadequate pain relief (minimum ≥50 mean on VAS with prior therapies lasting ≥3 months.
  10. In the judgment of the Investigator, acceptable general medical condition
  11. Male and female participants who are heterosexually active and not surgically sterile or must agree to use effective , including abstinence, for the duration of the study and for 3 months after the study is completed
  12. Have suitable facet joint anatomy for intra-articular injection
  13. Willing and able to return for the follow-up (FU) visits
  14. Able to reliably provide pain assessment (FAST test score R2≥0.7)
  15. Able to read and understand study instructions, and willing and able to comply with all study procedures

Exclusion criteria

Exclusion Criteria:

  1. , allergy, or significant reaction to any ingredient of the study drug, including double-stranded DNA, mannose, and sucrose
  2. Scheduled surgical procedure or nerve ablation to joint within the next 6 months; participant agrees not to schedule a surgical procedure, nerve ablation, or added facet injection within 6 months of study treatment
  3. High peri-operative risks which in the judgment of the investigator preclude a safe facet joint injection procedure (e.g. extreme obesity putting injection accuracy at risk, etc.)
  4. Current treatment with (systemic therapy [equivalent to >10mg/day prednisone] or other strong immunosuppressant)
  5. History of immunosuppressive therapy; high-potency systemic steroids in the last 3 months.
  6. Currently receiving systemic chemotherapy or radiation therapy for
  7. hepatic disease as indicated by clinical laboratory results ≥3 times the for any liver function test (e.g., , alanine aminotransferase, lactate dehydrogenase)
  8. Severe anemia (Grade 3; \<8.0 g/dL, \<4.9 mmol/L, \<80 g/L; transfusion indicated), Grade 1 white cell counts (lymphocytes \<LLN - 800/mm3; \<LLN - 0.8 x 109 /L, neutrophils \<LLN - 1500/mm3; \<LLN - 1.5 x 109 /L)
  9. Positive serology with reflex for , virus, or virus within 4 weeks of commencing the study
  10. Significant neuropsychiatric conditions; dementia, major depression, or altered mental state that in the opinion of the Investigator will interfere with study participation
  11. Current treatment with systemic antibiotics or antivirals (EXCEPTION: topical treatments)
  12. Current treatment with anticoagulants, other than low-dose aspirin
  13. Known or suspected history of active alcohol or intravenous/oral drug abuse within 1 year before the screening visit
  14. Use of any drug or device within 1 month before enrollment or current participation in a trial that included intervention with a drug or device; or currently participating in an investigational drug or device study.
  15. Any condition that, in the opinion of the Principal Investigator, could compromise the safety of the participant, the participant's ability to communicate with the study staff, or the quality of the data
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Sterile phosphate-buffered saline for injection Single 1mL injection into the facet joint

    Biological: XT-150

  • Experimental
    XT-150 Dose #1

    Lower dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint

    Biological: XT-150

  • Experimental
    XT-150 Dose #2

    Higher dose of XT-150 sterile solution for injection Single 1 mL injection into the facet joint

    Biological: XT-150

Interventions

  • BiologicalXT-150

    non-viral Plasmid DNA encoding an IL-10 variant transgene

06

What researchers measure

Primary outcomes

  1. Visual analog scale (VAS)

    0 - 100, 100 worst possible pain

    Time frame: 6 months

Secondary outcomes

  1. Oswestry Disability Index

    10 dimensions, 0 - 5 score in each, with 5 as worst score in a dimension

    Time frame: 6 months

07

Study locations

1 site
  • Alfred Health
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: No — Not applicable. All patient records are de-identified

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04841512
Lead sponsor
Xalud Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Oct 2021 (estimated)
Primary completion
Mar 1, 2022
Completion
Mar 1, 2022
Last update
Mar 17, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: XT-150

Start the discussion